Cerenome, Inc. (CNSY)
0.6301
-0.07
(-10.29%)
USD |
NASDAQ |
Nov 20, 16:00
0.6301
0.00 (0.00%)
After-Hours: 20:00
Cerenome Enterprise Value : 4.075M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 4.075M |
| November 19, 2026 | 4.645M |
| November 18, 2026 | 4.680M |
| November 17, 2026 | 4.077M |
| November 16, 2026 | 4.743M |
| November 13, 2026 | 6.598M |
| November 12, 2026 | 5.182M |
| November 11, 2026 | 5.422M |
| November 10, 2026 | 4.453M |
| November 09, 2026 | 3.60M |
| November 06, 2026 | 4.174M |
| November 05, 2026 | 4.389M |
| November 04, 2026 | 6.136M |
| November 03, 2026 | 9.354M |
| November 02, 2026 | 12.58M |
| October 30, 2026 | 12.51M |
| October 29, 2026 | 12.82M |
| October 28, 2026 | 12.82M |
| October 27, 2026 | 12.19M |
| October 26, 2026 | 11.48M |
| October 23, 2026 | 12.03M |
| October 22, 2026 | 12.90M |
| October 21, 2026 | 12.74M |
| October 20, 2026 | 12.35M |
| October 19, 2026 | 12.11M |
| Date | Value |
|---|---|
| October 16, 2026 | 12.51M |
| October 15, 2026 | 13.92M |
| October 14, 2026 | 12.43M |
| October 13, 2026 | 12.82M |
| October 12, 2026 | 13.37M |
| October 09, 2026 | 14.32M |
| October 08, 2026 | 13.22M |
| October 07, 2026 | 11.99M |
| October 06, 2026 | 11.64M |
| October 05, 2026 | 11.40M |
| October 02, 2026 | 11.72M |
| October 01, 2026 | 13.14M |
| September 30, 2026 | 13.85M |
| September 29, 2026 | 5.054M |
| September 28, 2026 | 6.223M |
| September 25, 2026 | 6.004M |
| September 24, 2026 | 5.127M |
| September 23, 2026 | 5.712M |
| September 22, 2026 | 6.296M |
| September 21, 2026 | 5.346M |
| September 18, 2026 | 6.296M |
| September 17, 2026 | 6.296M |
| September 16, 2026 | 6.369M |
| September 15, 2026 | 6.954M |
| September 14, 2026 | 7.320M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Ernexa Therapeutics, Inc. | -3.028M |
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.657M |
| Revenue (Quarterly) | 0.722M |
| Total Expenses (Quarterly) | 9.379M |
| EPS Diluted (Quarterly) | -1.144 |
| Gross Profit Margin (Quarterly) | -48.34% |
| Profit Margin (Quarterly) | -1.20K% |
| Earnings Yield | -718.1% |
| Normalized Earnings Yield | -725.27 |